Nurix Therapeutics, Inc. (NRIX) stock
NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$14.24−0.49 (-3.33%)
Close on Nov 17, 2026Market cap $1.56BP/E 6.2Yield 0.00%
Nurix Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Nurix Therapeutics's operating income for the twelve months ending Aug 31, 2026 was $289.66M. For fiscal 2025 it was -$285.67M. The highest annual figure on record is -$22.24M in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | -$285.67M | – |
| FY2024 | Nov 30, 2024 | -$213.03M | – |
| FY2023 | Nov 30, 2023 | -$155.06M | – |
| FY2022 | Nov 30, 2022 | -$183.87M | – |
| FY2021 | Nov 30, 2021 | -$117.89M | – |
| FY2020 | Nov 30, 2020 | -$64.98M | – |
| FY2019 | Nov 30, 2019 | -$22.24M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Aug 31, 2026 | $559.45M | – |
| Q2 FY2026CQ2 2026 | May 31, 2026 | -$94.20M | – |
| Q1 FY2026CQ1 2026 | Feb 28, 2026 | -$92.50M | – |
| Q4 FY2025CQ4 2025 | Nov 30, 2025 | -$83.10M | – |
| Q3 FY2025CQ3 2025 | Aug 31, 2025 | -$91.39M | – |
| Q2 FY2025CQ2 2025 | May 31, 2025 | -$48.32M | – |
| Q1 FY2025CQ1 2025 | Feb 28, 2025 | -$62.86M | – |
| Q4 FY2024CQ4 2024 | Nov 30, 2024 | -$64.66M | – |
| Q3 FY2024CQ3 2024 | Aug 31, 2024 | -$54.61M | – |
| Q2 FY2024CQ2 2024 | May 31, 2024 | -$48.54M | – |
| Q1 FY2024CQ1 2024 | Feb 29, 2024 | -$45.22M | – |
| Q4 FY2023CQ4 2023 | Nov 30, 2023 | -$45.33M | – |
| Q3 FY2023CQ3 2023 | Aug 31, 2023 | -$40.01M | – |
| Q2 FY2023CQ2 2023 | May 31, 2023 | -$26.77M | – |
| Q1 FY2023CQ1 2023 | Feb 28, 2023 | -$42.95M | – |
| Q4 FY2022CQ4 2022 | Nov 30, 2022 | -$48.69M | – |
| Q3 FY2022CQ3 2022 | Aug 31, 2022 | -$46.72M | – |
| Q2 FY2022CQ2 2022 | May 31, 2022 | -$45.72M | – |
| Q1 FY2022CQ1 2022 | Feb 28, 2022 | -$42.74M | – |
| Q4 FY2021CQ4 2021 | Nov 30, 2021 | -$37.95M | – |
| Q3 FY2021CQ3 2021 | Aug 31, 2021 | -$29.00M | – |
| Q2 FY2021CQ2 2021 | May 31, 2021 | -$26.41M | – |
| Q1 FY2021CQ1 2021 | Feb 28, 2021 | -$24.52M | – |
| Q4 FY2020CQ4 2020 | Nov 30, 2020 | -$20.01M | – |
| Q3 FY2020CQ3 2020 | Aug 31, 2020 | -$19.19M | – |
| Q2 FY2020CQ2 2020 | May 31, 2020 | -$13.23M | – |
| Q1 FY2020CQ1 2020 | Feb 29, 2020 | -$12.55M | – |
| Q4 FY2019CQ4 2019 | Nov 30, 2019 | -$13.56M | – |
| Q3 FY2019CQ3 2019 | Aug 31, 2019 | -$2.61M | – |
See a number that looks wrong?